• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Sunday, July 15, 2018

    Offline Date

    Tuesday, January 15, 2019

    ACPE Expiration Date

    Monday, May 17, 2021

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $0.00

    • Overview

      IBS-C and CIC are highly prevalent conditions that negatively impact Quality of Life and pose a significant economic burden on the healthcare system. Because so many patients self-treat the conditions, estimates of the number of Americans that suffer from IBS-C and CIC vary widely ranging from 2% to 27% of the population. Despite the $400 million dollars that are spent on laxatives each year, constipation still accounts for 2.5 million physician visits annually in the U.S. revealing a desperate need for improved patient counseling and knowledge of pharmacologic options beyond laxatives in pharmacies around the nation where millions of patients seek pharmacist recommendations. When traditional treatments, such as dietary manipulation and standard laxatives do not adequately treat or fail to treat IBS-C and CIC, pharmacists must be prepared to educate patients regarding the pharmacologic options available to relieve these frustrating and costly conditions.

      Handouts

      • Slide Document :   18066H01_4pp.pdf
      • Slide Document :   18066H01_2pp.pdf

      Financial Support By

      Synergy Pharmaceuticals
    • Pharmacist

      Identify strategies for pharmacists to assist in identifying inadequately treated patients and providing patient counseling regarding prescription treatment options that will facilitate communication with the physician.
      Describe the FDA approved pharmacologic treatment options for IBS-C and CIC, beyond laxatives, to include novel targets, efficacy data, primary contraindications, and adverse effects.
      Outline etiology and epidemiology of IBS-C and CIC in the U.S.

      Pharmacy Technician

      Identify common causes of IBS-C and CIC in the U.S.
      Identify FDA approved pharmacologic treatment options for IBS-C and CIC
      Recognize effective patient communication skills with the physician.

      Nurse

      Identify strategies for pharmacists to assist in identifying inadequately treated patients and providing patient counseling regarding prescription treatment options that will facilitate communication with the physician.
      Describe the FDA approved pharmacologic treatment options for IBS-C and CIC, beyond laxatives, to include novel targets, efficacy data, primary contraindications, and adverse effects.
      Outline etiology and epidemiology of IBS-C and CIC in the U.S.
    • Activity Type

      Knowledge

      CE Broker

      20-628395

      Universal Activity Number

      Pharmacist 0798-0000-18-066-H01-P
      Pharmacy Technician 0798-0000-18-066-H01-T
      Nurse 0798-0000-18-066-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).